Medetomidine biocide extension 2026: what changes for marine manufacturers

Key data

Manufacturers and distributors of antifouling biocides for vessels containing medetomidine have the green light to continue operating normally. The Commission Implementing Decision (EU) 2026/1089, published on 22 May 2026, extends the approval of this active substance for use in biocides of product type 21, avoiding a legal vacuum that would have blocked the commercialization of these products.

The reason is technical and administrative: the medetomidine re-evaluation process has not been completed within the planned timeframe. The Commission, rather than allowing the approval to expire, extends it until a final resolution is reached. This is common under the Regulation (EU) 528/2012 on biocides, which regulates the authorization of active substances throughout the European Union.

What does this regulation establish?

The decision delays the expiration date of the approval of medetomidine as an active substance in biocides of product type 21. These products are coatings and antifouling paints applied to vessel hulls to prevent the accumulation of marine organisms (algae, barnacles, mussels, etc.).

The Regulation (EU) 528/2012 establishes that no active substance can be used in biocides without being approved at European level. When an approval is in the renewal process and technical evaluation is delayed, the Commission may extend the existing approval to avoid disrupting the market. That is exactly what this decision does.

Economic and operational impact

For companies in the sector, the immediate impact is positive and ensures continuity: there is no interruption in the manufacturing, distribution, or sales chain. No changes to formulation, new product registrations, or stock withdrawal are required.

However, the medium-term impact depends on the outcome of the ongoing re-evaluation. There are three possible scenarios:

• Renewal without changes: Medetomidine remains approved under the same conditions. No additional impact.
• Renewal with conditions: Restrictions are imposed on concentration, application, or labeling. This would require product reformulation and updating of technical data sheets and product authorizations.
• Non-renewal: Medetomidine is excluded from the European market for TP21 biocides. Companies would need to seek alternative approved active substances, reformulate, and re-register their products. This is the scenario with the highest cost and operational impact.

The key is that the extension buys time but does not eliminate uncertainty. Companies that depend on medetomidine as their primary active substance should prepare alternative scenarios.

Who does it affect?

• Manufacturers of antifouling paints for vessel hulls that use medetomidine as an active substance.
• Distributors and wholesalers of product type 21 biocides with medetomidine in their catalog.
• Marine maintenance companies that apply or commercialize these products as part of their services.
• Importers of TP21 biocides with medetomidine from third countries for distribution in the EU.
• R&D and regulatory departments of chemical companies working on formulations for the marine sector.

Practical example

A Spanish manufacturer of antifouling paints has three product references in its catalog whose primary active substance is medetomidine. These products are authorized as product type 21 biocides and are sold to shipyards and marinas in Spain and Portugal.

Without the extension, the expiration of medetomidine approval would have forced this company to withdraw those products from the market until the re-evaluation was resolved, with the resulting impact on sales, customer contracts, and stock management.

Thanks to the Commission Implementing Decision (EU) 2026/1089, the company can continue manufacturing and selling those three references normally during the extension period. However, its technical director and regulatory manager must actively monitor the re-evaluation process at the European Chemicals Agency (ECHA), because if the final resolution imposes restrictions, they will need time to reformulate and re-register the affected products.

What should companies do now?

1. Verify your product catalog: Identify which references contain medetomidine as an active substance and are authorized as TP21 biocides. This defines the real scope of impact on your company.
2. Confirm the validity of product authorizations: The extension of active substance approval does not replace the authorization of each specific biocide product. Verify that the national authorizations of your products remain valid.
3. Monitor the re-evaluation process: Follow publications from the ECHA and the EU Official Journal to learn about the progress and final resolution of the medetomidine re-evaluation.
4. Prepare a contingency plan: If medetomidine is a critical active substance in your portfolio, start analyzing approved alternatives for TP21 biocides now, so that a possible non-renewal does not catch you without room to react.
5. Inform your distribution chain: Communicate to distributors and customers that products with medetomidine maintain their legality during the extension period, avoiding unnecessary order cancellations or alarms.